EUVIMEDObjevte EUVIMED
Crossref

Use of glucagon‐like peptide‐1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease

Aakash Desai iD, Jessica Petrov, Jana G Hashash, Harsh Patel, Bhaumik Brahmbhatt, Gursimran S Kochhar iD, Francis A Farraye

Alimentary Pharmacology & Therapeutics · 2024-09 · 60 (5) · 620-632

DOI: 10.1111/apt.18138 ↗

At a glance

Journal article in Alimentary Pharmacology & Therapeutics, published online on 2024-06-27. Written by Aakash Desai and 6 co-authors. Institution: Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA. Major MEDLINE topics: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Colitis, Ulcerative, Glucagon-Like Peptide-1 Receptor Agonists. Cited 44 times so far (Crossref); 28 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) show anti‐inflammatory properties.

Aim

To evaluate their clinical impact on inflammatory bowel disease (IBD) outcomes.

Methods

Retrospective cohort study utilising the TriNetX database comparing IBD‐specific outcomes in patients with ulcerative colitis (UC) or Crohn's disease (CD) and type 2 diabetes mellitus (T2DM) on GLP‐1RA compared to oral hypoglycaemic agents. The primary outcome was hospitalisation requiring intravenous steroids and IBD‐related surgery within 3 years. We performed 1:1 propensity score matching (PSM) for demographics, co‐morbid conditions, BMI, laboratory values, HbA1c, and IBD medications including steroids.

Results

We identified 1130 patients in the UC GLP‐1RA cohort (mean age: 58.9 ± 11.6 years, 56.3% female, 70.2% White, 57.2% with obesity) and 1140 patients in the CD GLP‐1RA cohort (mean age: 56.7 ± 11.5, 61.9% female, 73.6% White, 56.2% with obesity). After PSM, there was no difference in the risk of intravenous steroid use (aHR: 1.21, 95% CI: 0.92–1.59) but a lower risk of colectomy (aHR: 0.37, 95% CI: 0.14–0.97) between the UC GLP‐1RA and control cohort. There was no difference in the risk of intravenous steroid use (aHR: 1.04, 95% CI: 0.80–1.34) but a lower risk of surgery (aHR: 0.55, 95% CI: 0.36–0.84) between the CD GLP‐1RA and CD control cohort. There was no difference in the risk of oral steroid use or advanced therapy initiation in the UC and CD GLP‐1RA than control cohorts.

Conclusions

We found an association between lower risk of IBD‐related surgery and GLP‐1RA use for T2DM in patients with UC or CD.

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsColitis, UlcerativeGlucagon-Like Peptide-1 Receptor AgonistsHumansFemaleMaleMiddle AgedRetrospective StudiesAgedAdultTreatment OutcomeCrohn DiseaseInflammatory Bowel DiseasesHospitalization

Substances

Hypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Authors and institutions

  • Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA.
  • Division of Gastroenterology and Hepatology, University of Kansas Medical Center, Kansas City, Kansas, USA.
  • Division of Gastroenterology & Hepatology, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.

ORCID profiles: Aakash Desai, Gursimran S Kochhar

Cite

APA

Desai, A., Petrov, J., Hashash, J. G., Patel, H., Brahmbhatt, B., Kochhar, G. S., & Farraye, F. A. (2024). Use of glucagon‐like peptide‐1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 60(5), 620-632. https://doi.org/10.1111/apt.18138

Vancouver

Desai A, Petrov J, Hashash JG, Patel H, Brahmbhatt B, Kochhar GS, et al. Use of glucagon‐like peptide‐1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. 2024;60(5):620-632. doi:10.1111/apt.18138

BibTeX
@article{Desai2024,
  author = {Desai, Aakash and Petrov, Jessica and Hashash, Jana G and Patel, Harsh and Brahmbhatt, Bhaumik and Kochhar, Gursimran S and Farraye, Francis A},
  title = {Use of glucagon‐like peptide‐1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  volume = {60},
  number = {5},
  pages = {620--632},
  doi = {10.1111/apt.18138}
}
Start for free →